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Summary
The eﬃcacy of an HIV vaccine to prevent infection is likely to depend on the genetic
variation of the exposing virus. This paper addresses the problem of using data on
the HIV sequences that infect vaccine eﬃcacy trial participants to 1) test for vaccine
eﬃcacy more powerfully than procedures that ignore the sequence data; and 2) evaluate
the dependence of vaccine eﬃcacy on the divergence of infecting HIV strains from the
HIV strain that is contained in the vaccine. Because hundreds of amino acid sites in each
HIV genome are sequenced, it is natural to treat the genetic divergence as a continuous
mark variable that accompanies each failure (infection) time. Problems 1) and 2) can
then be approached by testing whether the ratio of the mark-speciﬁc hazard functions
for the vaccine and placebo groups is unity or independent of the mark. We develop
nonparametric and semiparametric tests for these null hypotheses, and nonparametric
techniques for estimating the mark-speciﬁc relative risks. The asymptotic properties of
the procedures are established. In addition the methods are studied in simulations and
are applied to HIV genetic sequence data collected in the ﬁrst HIV vaccine eﬃcacy trial.
Keywords: Competing risks; Genetic data; Mark variable; Nonparametric statistics;
1Proportional hazards; Survival analysis.
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1. Introduction
In many studies involving the comparison of survival data from two treatment
groups, a mark variable is measured only in failures, and it is of interest to account
for this mark in comparing the failure experience. In this article, we develop testing
and estimation procedures to assess mark-speciﬁc relative risks. This departs from our
recent work (Gilbert et al., 2004) in which we developed a test for the dependence of a
single mark-speciﬁc hazard rate on the mark variable (i.e., the “one-sample” problem).
The two-sample problem addressed here is scientiﬁcally compelling, as elaborated below,
whereas the one-sample problem has limited relevance to clinical trials. Furthermore
our approach to the two-sample problem entails major diﬀerences in hypotheses and
inferential procedures compared to those used for the one-sample problem, and here we
expand the scope of research to include estimation as well as testing, and semiparametric
as well as nonparametric hypothesis testing.
We are motivated by applications in HIV vaccine eﬃcacy trials. The extensive ge-
netic diversity of HIV poses one of the greatest challenges to developing an AIDS vaccine
(Graham, 2002). Vaccine eﬃcacy to prevent infection, usually deﬁned in terms of the
hazard ratio between vaccine and placebo recipients, may decrease with the viral diver-
gence of a challenge HIV from the virus or viruses represented in the vaccine construct
(Gilbert et al., 1999). Detecting such a decrease can help guide the development of new
vaccines to provide greater breadth of protection. The relevance of our mark-speciﬁc
hazard function approach is that the “distance” between a subject’s infecting strain
and the nearest vaccine strain can be viewed as a mark variable that is only observed
in subjects who experience the event (HIV infection).
From 1998 to 2003 VaxGen Inc. conducted the world’s ﬁrst HIV vaccine eﬃcacy
trial (Flynn et al., 2005). HIV uninfected volunteers at high risk for acquiring HIV were
randomized to receive the vaccine AIDSVAX (n1 =3 ,598) or placebo (n2 =1 ,805).
2Subjects were monitored for 3 years for the primary study endpoint HIV infection. For
each subject who became HIV infected, the envelope glycoprotein (gp120) region of the
infecting virus was sequenced. Of the 368 subjects who acquired HIV, the sequence
data were collected for 336 subjects (217 of 241 vaccine; 119 of 127 placebo). VaxGen
hypothesized that the level of vaccine eﬃcacy would be higher against HIVs with gp120
amino acid sequences that were relatively similar to either of the two HIV strains (named
MN and GNE8) that were represented in the vaccine. The distance of each infecting
virus to MN and to GNE8 was measured by the percent mismatch in the aligned amino
acid sequences (i.e., Hamming distance) for three sets of positions hypothesized to be
important for neutralizing HIV (Wyatt et al., 1998): (1) the neutralizing face core of
gp120 that was crystalized; (2) the neutralizing face core plus the variable loop V2/V3
regions; and (3) the V3 loop. For each metric and infecting virus, the mark is deﬁned
as the minimum of the two distances to the MN and GNE8 reference sequences.
Gilbert et al. (1999) and Gilbert (2000) developed a semiparametric biased sampling
model as a tool for studying vaccine eﬃcacy as a function of a continuous mark, which
parametrically speciﬁes the relationship between vaccine eﬃcacy and the mark, and
leaves the distribution of the mark in the infected placebo group unspeciﬁed. However,
there are no data available for suggesting the correct parametric model, so nonpara-
metric methods are desirable. Furthermore, the earlier work is limited by conditioning
on infection, so odds ratios but not relative risks of infection can be estimated, and the
model treats HIV infection as a binary outcome, ignoring the time to HIV infection. The
methods presented here were developed because they are free from these limitations,
as they are nonparametric (though semiparametric procedures are also considered),
prospective, and incorporate the failure times.
We introduce tests for the hypothesis that the mark-speciﬁc risks in the two groups
coincide, and for the hypothesis that the relative mark-speciﬁc risk between the groups
is independent of the mark. The time Tk to endpoint and the mark variable Vk for a
representative individual in group k are assumed to be jointly absolutely continuous with
joint density fk(t,v). We only get to observe (Xk,δ k,δ kVk), where Xk =m i n {Tk,C k},
δk = I(Tk ≤ Ck), and Ck is a censoring time assumed to be independent of both Tk
3and Vk, k =1 ,2. When the failure time Tk is observed, δk =1a n dt h em a r kVk is
also observed, whereas if Tk is censored, the mark is unknown. Since the mark is only
observed for failures, it cannot be studied as a covariate in evaluating risk. We assume
that each mark variable Vk has known and bounded support; rescaling Vk if necessary,
this support is taken to be [0,1]. The mark-speciﬁc hazard rate in group k is
λk(t,v) = lim
h1,h2→0
P{Tk ∈ [t,t + h1),V k ∈ [v,v + h2)|Tk ≥ t}/h1h2 (1.1)
and the mark-speciﬁc cumulative incidence function is
Fk(t,v) = lim
h2→0
P{Tk ≤ t,Vk ∈ [v,v + h2)}/h2, (1.2)
k =1 ,2, with t ranging over a ﬁxed interval [0,τ]. These functions are natural extensions
of the cause-speciﬁc hazard function and cumulative incidence function that have been
extensively studied for a discrete mark variable (e.g., Prentice et al., 1978). Similar
to the discrete mark case, the functions (1.1) and (1.2) are related by the equation
Fk(t,v)=
  t
0 λk(s,v)Sk(s)ds, where Sk(t) is the survival function for group k,a n da r e
estimable from the observed group k competing risks failure time data. In the case of
a discrete mark variable, Gray (1988) developed a nonparametric test for comparing
cumulative incidence functions among groups, at a speciﬁed value of the mark variable.
A standard measure of vaccine eﬃcacy to prevent infection at time t is the relative
reduction in hazard due to vaccination: VE(t)=1− λ1(t)/λ2(t), see Halloran et al.
(1997). It is natural to extend this deﬁnition to allow the vaccine eﬃcacy to depend on
viral divergence: VE(t,v)=1− λ1(t,v)/λ2(t,v). This parameter has a useful approxi-
mate interpretation as the relative multiplicative reduction (vaccine versus placebo) in
the probability that one exposure to strain v at time t (by a sexual or needle contact)
leads to infection (Halloran et al., 1992). This interpretation follows by randomization,
blinding, and the fact that HIV infection is a rare event in HIV vaccine eﬃcacy trials
(typically occurring in fewer than 10-15% of subjects), which together imply that the
amount of exposure to HIV strains of distance v is approximately equal in the vaccine
and placebo groups throughout the follow-up period.
To account for the mark in testing for vaccine eﬃcacy, we develop tests for the null
4hypothesis
H0
0: λ1(t,v)=λ2(t,v)f o r( t,v) ∈ [0,τ] × [0,1]
against the following alternative hypotheses:
H0
1: λ1(t,v) ≤ λ2(t,v) for all (t,v) ∈ [0,τ] × [0,1];
H0
2: λ1(t,v)  = λ2(t,v)f o rs o m e ( t,v) ∈ [0,τ] × [0,1]
with strict inequality for some (t,v) ∈ [0,τ] × [0,1] in H0
1.T e s t i n g H0
0 evaluates
VE(t,v) = 0 for all t and v, i.e., whether there is any vaccine eﬃcacy against any
HIV strain. As we show in simulations, tests of H0
0 c a nh a v em u c hg r e a t e rp o w e rt h a n
standard tests of vaccine eﬃcacy that ignore the mark, i.e., that evaluate the null hy-
pothesis λ1(t)=λ2(t) for all t ∈ [0,τ]. A test ignoring the mark should be done in
conjunction with a test of H0
0, however, to assess the overall clinical/public health ben-
eﬁt of the vaccine. To illustrate the importance of carrying out both tests, if VE(t)=0
and VE(t,v) is positive (negative) for v ≤ (>)0 .5, then the vaccine clearly should not
be declared eﬀective, yet the analysis accounting for the mark would lead to follow-up
studies of the mechanism by which the vaccine impacted mark-speciﬁc infection risk.
If H0
0 is rejected, then it is of interest to assess if vaccine eﬃcacy varies with strain
distance. Accordingly, we also develop tests for
H0: λ1(t,v)/λ2(t,v) does not depend on v for t ∈ [0,τ]
against the following alternative hypotheses:
H1: λ1(t,v1)/λ2(t,v1) ≤ λ1(t,v2)/λ2(t,v2) for all v1 ≤ v2,t ∈ [0,τ];
H2: λ1(t,v1)/λ2(t,v1)  = λ1(t,v2)/λ2(t,v2)f o rs o m ev1 ≤ v2,t ∈ [0,τ]
with strict inequality for some t,v1,v 2 in H1. Because H0 and H1 can be re-expressed as
H0 :V E ( t,v)=V E ( t) for all t,v and H1 :V E ( t,v1) ≤ VE(t,v2) for all t,v1 ≥ v2 (with
< for some v1 >v 2), testing H0 versus H1 assesses whether vaccine eﬃcacy decreases
with HIV sequence divergence. Scientiﬁcally this is the most interesting hypothesis to
assess.
To develop suitable test statistics, we will exploit the observation that H0 holds
if and only if the mark-speciﬁc relative risk coincides with the ordinary relative risk,
5i.e., λ1(t,v)/λ2(t,v)=λ1(t)/λ2(t) for all t,v,w h e r eλk(t)=
  1
0 fk(t,v)dv/Sk(t)=
  1
0 λk(t,v)dv is the group-k hazard irrespective of the mark. In Section 2 we introduce
the proposed procedures for testing H0
0 and H0. Large sample results and a simulation
technique needed to implement the test procedures are developed in Section 3. In
Section 4 we discuss nonparametric estimation of the mark-speciﬁc vaccine eﬃcacy. We
report the results of a simulation experiment in Section 5, and an application to data
from the VaxGen trial is provided in Section 6. Section 7 contains concluding remarks.
Proofs of the main results are collected in the Appendix.
2. Test Procedure
We base our approach on estimates of the doubly cumulative mark-speciﬁc hazard
functions Λk(t,v)=
  v
0
  t
0 λk(s,u)dsdu, k =1 ,2. Given observation of i.i.d. replicates
(Xki,δ ki,δ kiVki),
i =1 ,...,n k,o f( Xk,δ k,δ kVk), k =1 ,2, the nonparametric maximum likelihood esti-
mator (MLE) of Λk(t,v) is provided by the Nelson–Aalen-type estimator
ˆ Λk(t,v)=
  t
0
Nk(ds,v)
Yk(s)
,t ≥ 0,v ∈ [0,1], (2.1)
where Yk(t)=
 nk
i=1 I(Xki ≥ t) is the size of the risk set for group k at time t,a n d
Nk(t,v)=
nk  
i=1
I(Xki ≤ t,δki =1 ,V ki ≤ v)
is the marked counting process with jumps at the uncensored failure times Xki and
associated marks Vki, see Huang and Louis (1998, (3.2)).
Our tests of H0
0 are based on comparing ˆ Λ1(t,v)a n dˆ Λ2(t,v), and of H0 are based
on comparing the nonparametric MLE of Λ1(t,v)−Λ2(t,v) with an estimate under H0.
Since H0 is equivalent to Λ1(t,v)=
  t
0[λ1(s)/λ2(s)]Λ2(ds,v) for all t,v, under H0 we
may estimate the diﬀerence Λ1(t,v) − Λ2(t,v)b y
  t
0[(ˆ λ1(s)/ˆ λ2(s)) − 1]ˆ Λ2(ds,v), where
ˆ λk(t) is a nonparametric estimator of λk(t), as discussed below. Alternatively, un-
der a proportional marginal hazards assumption, λ1(t)/λ2(t)=e x p ( β), this diﬀerence
may be estimated by
  t
0[exp(ˆ β) − 1]ˆ Λ2(ds,v), where ˆ β is the maximum partial likeli-
hood estimator of β, which leads to a semiparametric test for H0. The nonparametric
6approach makes minimal assumptions but requires smoothing, whereas the semipara-
metric approach avoids smoothing and in principle may provide greater power when the
proportional hazards assumption holds.
For the nonparametric approach we estimate each hazard function λk(t)b yk e r n e l
smoothing:
ˆ λk(t)=
1
bk
  τ+δ
0
K
 
t − s
bk
 
dˆ Λk(s), (2.2)
where ˆ Λk(s)=
  t
0(1/Yk(s))dNk(s) is the Nelson–Aalen estimator of Λk(t)=
  t
0 λk(s)ds,
with Nk(t)=
 nk
i=1 I(Xki ≤ t,δki =1 ) .T h ek e r n e lK is a bounded symmetric function
with support [−1,1] and integral 1. The bandwidth bk is a positive parameter that
indicates the window [t−bk,t+bk]o v e rw h i c hˆ Λk(t) is smoothed, and converges to zero
as nk →∞ . We choose kernel esimators because they are uniformly consistent under
assumptions (see Theorem IV.2.2 in Andersen et al., 1993), a property that is needed
for the theoretical justiﬁcation given later.
2.1 Test Processes and Test Statistics
Based on the above discussion, we introduce test processes of the form
Lr
n(t,v)=
 
n1n2
n
  t
a
Hn(s)
 
ˆ Λ1(ds,v) − ˆ r(s)ˆ Λ2(ds,v)
 
(2.3)
for t ≥ 0,0 ≤ v ≤ 1, where Hn(·) is a suitable weight process converging to a non-random
function H(·)a n da ≥ 0. The superscript r reﬂects the choice of process ˆ r(s)i nt h et e s t
process and indicates whether it is used to test H0
0 (indicated by r as 1, corresponding to
ˆ r(s)=1 ) ,t ot e s tH0 nonparametrically (indicated by r as np;ˆ r(s)=ˆ λ1(s)/ˆ λ2(s)) or to
test H0 semiparametrically (indicated by r as sp;ˆ r(s)=e x p (ˆ β)). A simple calculation
shows that for r as np,[ ·] in (2.3) compares ˆ Λ1(ds,v) − ˆ Λ2(ds,v) to the nonparametric
estimate of Λ1(ds,v) − Λ2(ds,v) under H0 described above. The parallel result holds
for r as sp, using the semiparametric estimate of Λ1(ds,v) − Λ2(ds,v) under H0.
A variety of test statistics can be formulated as functionals of Lr
n(t,v). We develop
integration type and supremum type statistics. With wV (v) a known nonnegative weight
function, large values of the following test statistics provide evidence against H0
0 in the
direction of H1
0 (ﬁrst two statistics) or H2
0 (second two statistics):
ˆ U1
1 = L1
n(τ,1), ˆ U1
2 =
  1
0
wV (v)L1
n(τ,v)dv, (2.4)
7ˆ U1
3 = |L1
n(τ,1)|, ˆ U1
4 =
  1
0
wV (v)(L1
n(τ,v))2dv. (2.5)
For testing H0, let yk(t)=P(Xk ≥ t), let ˜ τ =s u p {t:y1(t) > 0a n dy2(t) > 0},
and assume τ<˜ τ. With kernel smoothing, the bias term of ˆ λk(t)i so fo r d e rO(b2
k)
for the inner points in [bk, ˜ τ − bk] and of order O(bk) for the boundary points in (0,b k)
or (˜ τ − bk, ˜ τ). To simplify the proofs and the conditions on the rates of convergence
concerning bk,w et a k ea>0 and construct the test statistics from the process Lr
n(t,v)
over a ≤ t ≤ τ,0 ≤ v ≤ 1. In practice, however, there would be no harm in taking
a = 0 in order to use as much of the data as possible (this is done in the simulations
and application).
Set Δr
n(t,v1,v 2)=Lr
n(t,v1)+Lr
n(t,v2) − 2Lr
n(t,(v1 + v2)/2). For r as np or sp,t h e
following test statistics measure departures from H0 in the direction of H1 (ˆ Ur
1)o rH2
(ˆ Ur
2):
ˆ Ur
1 =s u p
v1<v2
sup
0≤t1<t2<τ
[Δr
n(t2,v 1,v 2) − Δr
n(t1,v 1,v 2)], (2.6)
ˆ Ur
2 =s u p
v1<v2
sup
0≤t1<t2<τ
|Δr
n(t2,v 1,v 2) − Δr
n(t1,v 1,v 2)|. (2.7)
To motivate the test statistics ˆ Ur
1 and ˆ Ur
2, we note from the proof of Theorem 2 in
the Appendix that (n/n1n2)1/2[Δr
n(t2,v 1,v 2) − Δr
n(t1,v 1,v 2)] converges in probability
to δ(t1,t 2,v 1,v 2)=
  t2
t1
  v2
v1+v2
2
H(s)(λ1(s,v)−r(s)λ2(s,v))dv ds−
  t2
t1
  v1+v2
2
v1
H(s)(λ1(s,v)−r(s)λ2(s,v))dv ds,
where r(s)=λ1(s)/λ2(s)o re x p ( β). Under H0, δ(t1,t 2,v 1,v 2) = 0 for all t1,t 2 ∈ [0,τ]
and v1,v 2 ∈ [0,1]. Under H1 and some smoothness conditions, δ(t1,t 2,v 1,v 2) > 0f o r
some t1 <t 2 ∈ [0,τ]a n dv1 <v 2 ∈ [0,1]. Therefore large values of ˆ Ur
1 (ˆ Ur
2)p r o v i d e
evidence against H0 in the direction of H1 (H2).
In the next section, we provide results that all three processes Lr
n(t,v) (indexed by
r) converge weakly to a Gaussian process under the appropriate null hypothesis. We
also state results (with proofs given in the Appendix) on the consistency of the proposed
tests against their alternatives, and describe a simulation procedure for determining the
critical values of the ˆ Ur
j .
83. Large-Sample Results
We present the asymptotic results for the nonparametric tests of H0. Parallel results
for the semiparametric tests of H0 and the tests of H0
0 follow by similar but simpliﬁed
arguments; these results are brieﬂy stated at the end of this section.
We begin by deﬁning notation that is used in the sequel. Let γk(t,v)=P(Xk ≤
t,δk =1 ,V k ≤ v),k=1 ,2. By the Glivenko–Cantelli Theorem, Nk(t,v)/nk and Yk(t)/nk
converge almost surely to γk(t,v)a n dyk(t), uniformly in (t,v) ∈ [0,∞) × [0,1] and
t ∈ [0,∞), respectively. Note that we may write λk(t,v)=fk(t,v)/STk(t), where
STk(t)=P(Tk ≥ t)a n dfk(t,v)i st h ej o i n td e n s i t yo f( Tk,V k) for group k.A l s o
λk(t)=fTk(t)/STk(t), where fTk(t) is the density of Tk for group k.L e t D(I)t h e
Skorohod space of the functions on a K-dimensional rectangle I that are continuous from
above with limits from below (Bickel and Wichura, 1971), and C(I) be the subspace of
continuous functions on I.
3.1 Asymptotic Distributions of the Test Statistics
Let Z1(t,v)a n dZ2(t,v) be two independent Gaussian processes deﬁned by
Zk(t,v)=
  t
0
1
yk(s)
G
(k)
1 (ds,v) −
  t
0
G
(k)
2 (s)
yk(s)2 γk(ds,v),k =1 ,2, (3.1)
where G
(k)
1 (t,v)a n dG
(k)
2 (t) are continuous mean zero Gaussian processes with covari-
ances
Cov(G
(k)
1 (s,u),G
(k)
1 (t,v)) = γk(s ∧ t,u ∧ v) − γk(s,u)γk(t,v),
Cov(G
(k)
2 (s),G
(k)
2 (t)) = yk(s ∨ t) − yk(s)yk(t),
Cov(G
(k)
1 (s,u),G
(k)
2 (t)) = (γk(s,u) − γk(t−,u))I(t ≤ s) − γk(s,u)yk(t).
Let a(t)=1 /λ2(t)a n d0<κ= limn→∞n1/n < 1. Deﬁne
Lnp(t,v)=
√
1 − κ
   t
a
H(s)Z1(ds,v) −
  t
a
H(s)a(s)Λ 
2s(s,v)Z1(ds,1)
 
−
√
κ
   t
a
H(s)r(s)Z2(ds,v) −
  t
a
H(s)r(s)a(s)Λ 
2s(s,v)dZ2(ds,1)
 
, (3.2)
where Λ 
2t(t,v)=∂Λ2(t,v)/∂t.
Our ﬁrst result describes the limiting null distribution of the test process and the
test statistics.
9Theorem 1 Assume the following conditions: The weight process Hn(t) is left con-
tinuous with total variation over t ∈ [0,τ + δ] bounded in probability, for τ + δ<˜ τ,
δ>0. There exists a uniform continuous function H(t) with bounded variation such
that sup0≤t≤τ+δ |Hn(t) − H(t)|
P −→0. λk(t) for k =1 ,2 are continuously diﬀerentiable
and bounded away from zero on [0,τ+ δ], λ2(t,v) > 0 and ∂2Λ2(t,v)/∂t2 is continuous
on [0,τ + δ] × [0,1]. P(Ck ≥ τ + δ) > 0. The symmetric kernel function K(t) has
bounded support on [−1,1] and is twice continuously diﬀerentiable. nkb3
k/logb−1
k →∞
and nkb4
k → 0 for k =1 ,2. Then, under H0
Lnp
n (t,v)
D −→Lnp(t,v) (3.3)
in D([a,τ] × [0,1]) as n →∞ .
The proof of Theorem 1 immediately follows from Proposition 1 given in the Ap-
pendix. The conditions on the rates of convergence are satisﬁed if bk = n−ν
k for
1/4 <ν<1/3.
Let Ur
j be deﬁned the same as ˆ Ur
j in (2.6)-(2.7), with Lr
n(t,v) replaced with Lr(t,v).
By the continuous mapping theorem, ˆ U
np
j
D −→U
np
j under H0,s oP(ˆ U
np
j >c jα) → α,
where cjα is the upper α-quantile of U
np
j . However, the cjα are unknown and very
diﬃcult to estimate due to the complicated nature of the limit process Lnp(t,v). In the
next section we provide a Monte Carlo procedure to obtain each cjα.
Theorem 2 establishes that each ˆ U
np
j is consistent against its alternative.
Theorem 2 In addition to the conditions given in Theorem 1, assume that λ1(t,v) and
λ2(t,v) are continuous and that H(t) > 0 on [0,τ] ×[0,1].T h e n ,P(ˆ U
np
1 >c 1α) → 1 as
n →∞under H1, and P(ˆ U
np
2 >c 2α) → 1 as n →∞under H2.
Theorems 1 and 2 also hold for Lsp
n and ˆ U
sp
j ,j =1 ,2, under the same conditions
except that the conditions on λk(t) are replaced by the proportional marginal hazards
assumption λ1(t)/λ2(t)=e x p ( β). Theorem 1 holds for L1
n under the same conditions
minus any assumptions about λk(t). We note that the tests ˆ U1
j are not consistent tests
since they are based on L1
n(τ,v) — by integrating over t ∈ [0,τ], diﬀerences between the
two mark-speciﬁc hazard functions may cancel in a case that the marginal hazards cross.
10Consistent supremum versions of these statistics are easily constructed, however. By
accumulating the contrast at the end of follow-up τ,the tests based on ˆ U1
j presented here
may be more powerful than their supremum counterparts, in cases that the marginal
hazards do not strongly cross.
3.2 Gaussian Multipliers Simulation Procedure
We now describe a Gaussian multipliers technique for simulating each of the test
processes Lnp
n (t,v),L sp
n (t,v), and L1
n(t,v) under the null hypothesis, cf. Lin et al. (1993).
Note that γk(ds,v)/yk(s)=
  v
0 λk(s,u)duds. By (A.7) in the Appendix and the continu-
ous mapping theorem, we obtain the result that
  t
a y−1
k (s)
√
nk(Nk(ds,v)−Yk(s)Λk(ds,v))
=
  t
a
y−1
k (s)
√
nk(Nk(ds,v)/nk − γk(ds,v)) −
  t
a
y−2
k (s)
√
nk(Yk(s)/nk − yk(s))γk(ds,v)
D −→Zk(t,v). (3.4)
Deﬁne the process ˜ Lnp(t,v) by replacing Zk(t,v), k =1 ,2, in Lnp(t,v) given in
(3.2) with the term on the left side of (3.4) and replacing κ with n1/n. Applying
the continuous mapping theorem again, we have ˜ Lnp(t,v)
D −→Lnp(t,v). Let Nki(t,v)=
I(Xki ≤ t,δki =1 ,V ki ≤ v)a n dYki(t)=I(Xki ≥ t), k =1 ,2. It follows that
˜ Lnp(t,v)=
 
n2/nn1
−1/2
n1  
i=1
h1i(t,v) −
 
n1/nn2
−1/2
n2  
i=1
h2i(t,v); (3.5)
h1i(t,v)=
  t
a
H(s)y−1
1 (s)(N1i(ds,v) − Y1i(s)Λ1(ds,v))
−
  t
a
H(s)a(s)Λ 
2s(s,v)y−1
1 (s)(N1i(ds,1) − Y1i(s)Λ1(ds,1))
h2i(t,v)=
  t
a
H(s)r(s)y−1
2 (s)(N2i(ds,v) − Y2i(s)Λ2(ds,v))
−
  t
a
H(s)b(s)Λ 
2s(s,v)y−1
2 (s)(N2i(ds,1) − Y2i(s)Λ2(ds,1))
with a(s)=1 /λ2(s), b(s)=λ1(s)/(λ2(s))2,a n dΛ  
2s(s,v)=∂Λ2(s,v)/∂s.
Deﬁne ˆ hki(t,v) by replacing, in hki(t,v), H(s)w i t hHn(s), yk(s)w i t hYk(s)/nk, a(s)
with ˆ a(s), and Λ 
2s(s,v) with a suitable smooth uniformly consistent estimate ˆ Λ 
2s(s,v)
on [a,τ] × [0,1]. Let Wki,i =1 ,...,n k,k =1 ,2, be i.i.d. standard normal random
variables. Let
Lnp∗
n (t,v)=
 
n2
n
n1
−1/2
n1  
i=1
ˆ h1i(t,v)W1i −
 
n1
n
n2
−1/2
n2  
i=1
ˆ h2i(t,v)W2i. (3.6)
11We show that the conditional weak limit of the process Lnp∗
n (t,v) given the observed
data is the same as the weak limit of Lnp
n (t,v) under the null hypothesis H0.N o t et h a t
the two terms in (3.2) and (3.6) are independent. It is easy to show that for any two
points (t,v)a n d( s,w)i n[ a,τ]×[0,1], n−1
k
 nk
i=1 ˆ h1i(t,v)ˆ h1i(s,w)
P −→E[h1i(t,v)h1i(s,w)],
since ˆ hki(t,v)
P −→hki(t,v)a sn →∞ . Thus, the conditional covariance of Lnp∗
n (t,v)
converges to the covariance of Lnp(t,v). It is left to show that the process Lnp∗
n (t,v)i s
tight (see Appendix).
Theorem 3 Under the conditions of Theorem 1, conditional on the observed data,
Lnp∗
n (t,v)
D −→
Lnp(t,v) in D([a,τ] × [0,1]) under H0 as n →∞ ,w h e r eLnp(t,v) is given in (3.2).
Theorem 3 also holds for the semiparametric tests of H0, using the following modiﬁed
test processes. By the proof of Proposition 1, under H0
Lsp
n (t,v)=
 
n2
n
  t
0
Hn(s) ˆ Z1(ds,v) −
 
n1
n
  t
0
Hn(s)exp(ˆ β) ˆ Z2(ds,v)
−
 
n1n2
n
  t
0
Hn(s)[exp(ˆ β) − exp(β)]Λ2(ds,v). (3.7)
Let Un(β)a n dJn(β) be the score function and information matrix under the pro-
portional marginal hazards model. It is easy to obtain that
Un(β)=
n1  
i=1
  τ
0
 n2
j=1 Y2j(s)
 n1
j=1 Y1j(s)exp(β)+
 n2
j=1 Y2j(s)
N1i(ds,1)
−
n2  
i=1
  τ
0
 n1
j=1 Y1j(s)exp(β)
 n1
j=1 Y1j(s)exp(β)+
 n2
j=1Y2j(s)
N2i(ds,1)
≡
n1  
i=1
U1i(β) −
n2  
i=1
U2i(β);
Jn(β)=
2  
k=1
nk  
i=1
  τ
0
 n1
j=1 Y1j(s)
 n2
j=1 Y2j(s)exp(β)
(
 n1
j=1Y1j(s)exp(β)+
 n2
j=1 Y2j(s))2 Nki(ds,1).
A routine delta method and likelihood analysis yields n1/2(exp(ˆ β)−exp(β)) = exp(β)×
(n−1Jn(β))−1n−1/2Un(β)+op(1). From this result and (3.7), following the arguments
of Section , the distribution of Lsp
n (t,v) under H0 can be approximated by the following
process Lsp∗
n (t,v) given the observed data,
Lsp∗
n (t,v)=
 
n2
n
n1
−1/2
n1  
i=1
   t
0
Hn(s)(n1Y −1
1 (s))(N1i(ds,v) − Y1i(s)Λ1(ds,v))
12−
n1
n
exp(ˆ β)(n−1Jn(ˆ β))−1 ˆ U1i(ˆ β)
  t
0
Hn(s)ˆ Λ2(ds,v)
 
W1i
−
 
n1
n
n2
−1/2
n2  
i=1
   t
0
Hn(s)exp(ˆ β)(n2Y −1
2 (s))(N2i(ds,v) − Y2i(s)Λ2(ds,v))
−
n2
n
exp(ˆ β)(n−1Jn(ˆ β))−1 ˆ U2i(ˆ β)
  t
0
Hn(s)ˆ Λ2(ds,v)
 
W2i,
where ˆ U1i(ˆ β)a n dˆ U2i(ˆ β) are obtained from U1i(β)a n dU2i(β), respectively, with β,
Λ1(ds,1) and Λ2(ds,1) replaced by ˆ β, ˆ Λ1(ds,1) and ˆ Λ2(ds,1), respectively.
Similarly, the distribution of L1
n(t,v) under H0
0 can be approximated by L1∗
n (t,v)
given the observed data, where
L1∗
n (t,v)=
 
n1
n
n2
−1/2
n2  
i=1
  t
0
Hn(s)(n2Y −1
2 (s))(N2i(ds,v) − Y2i(s)Λ2(ds,v))W2i
−
 
n2
n
n1
−1/2
n1  
i=1
  t
0
Hn(s)(n1Y −1
1 (s))(N1i(ds,v) − Y1i(s)Λ1(ds,v))W1i.
3.3 Choice of Weight Process
In exploratory work it can be useful to examine a plot of the test process Lr
n(t,v)
with the weight process chosen to be Hn(t) = 1, and compare it with plots of (say) 5–20
realizations of the simulated reference process Lr∗
n (t,v). Large values of |L1(t,v)| for
some v and t suggest a departure from H0
0. Large values of Lnp
n (t1,v) − Lnp
n (t2,v)f o r
some v and some t1 <t 2,a sc o m p a r e dw i t ht h es a m ec o n t r a s ti nLnp∗
n (t,v), suggest a
departure from H0 in the direction of H1. Large absolute diﬀerences in Lnp
n (t,v)a c r o s s
diﬀerent marks v (as compared with the reference process) would suggest H2.T h i s
graphical procedure is illustrated in Section 6.
The test process is more variable at larger failure times, so it is advisable to choose
the weight process to downweight the upper tail of the integral, and we suggest
Hn(s)=
 
Y1(s)
n1
Y2(s)
n2
. (3.8)
The weight can also be chosen to increase power against speciﬁc alternatives (Sun,
2001). Furthermore the test can be made invariant to the order of the two groups by
including ˆ r(s)−1/2 in Hn(s).
4. Estimation of Mark-Specific Vaccine Efficacy
13Precise estimation of VE(t,v) introduced in Section 1 requires huge sample sizes,
because smoothing is required in both v and t, and generally eﬃcacy trials do not provide
suﬃcient samples (Gilbert et al., 2002). Accordingly, we consider an alternative notion
of mark-speciﬁc vaccine eﬃcacy deﬁned in terms of cumulative incidences:
VEc(t,v)=1− F1(t,v)/F2(t,v),
which we call cumulative vaccine eﬃcacy. This represents a time-averaged — rather
than instantaneous — measure of vaccine eﬃcacy and is much easier to estimate than
VE(t,v). We also consider the doubly cumulative vaccine eﬃcacy
VEdc(t,v)=1− P(T1 ≤ t,V1 ≤ v)/P(T2 ≤ t,V2 ≤ v),
which can be estimated without smoothing and with greater precision than VEc(t,v).
A nonparametric estimator of VEc(t,v)i sg i v e nb y  VE
c
(t,v)=1− ˆ F1(t,v)/ ˆ F2(t,v),
where
ˆ Fk(t,v)=
1
bk
  1
0
  t
0
ˆ Sk(s−)
Yk(s)
K
 
v − u
bk
 
Nk(ds,du), (4.1)
ˆ Sk(t) is the Kaplan–Meier estimate of Sk(t),K(·) is a boundedsymmetric kernel function
with support [−1,1] and integral 1, and bk > 0 is a bandwidth. The estimator ˆ Fk(t,v)i s
the continuous analog of the estimator that has been used for a discrete mark (Prentice
et al., 1978).
If F1(t,v)  =0a n dF2(t,v)  = 0, a 100(1 − α)% pointwise conﬁdence interval
for VEc(t,v) can be computed by transforming symmetric conﬁdence limits about
log(F1(t,v)/F2(t,v)) :
1 −
 
1 −   VE
c
(t,v)
 
exp
⎛
⎝±zα/2
   
 
 
  Var{ ˆ F1(t,v)}
ˆ F1(t,v)2 +
  Var{ ˆ F2(t,v)}
ˆ F2(t,v)2
⎞
⎠; (4.2)
  Var{ ˆ Fk(t,v)} =
1
b2
k
  1
0
  t
0
 
ˆ Sk(s−)
Yk(s)
K
 
v − u
bk
  2
Nk(ds,du).
To estimate VEdc(t,v), each P(Tk ≤ t,Vk ≤ v) is simply estimated by
  t
0
 
ˆ Sk(s−)/Yk(s)
 
Nk(ds,v), the standard estimator for the discrete cumulative incidence function for cause
of failure deﬁned by V ≤ v,and its variance is estimated by
  t
0
 
ˆ Sk(s−)/Yk(s)
 2
Nk(ds,v).
145. Simulation Experiment
The simulations are based on the features of the VaxGen trial described in the
Introduction. We study performance of the test statistics ˆ U1
j ,j =1 ,2,3,4; ˆ U
np
j and
ˆ U
sp
j ,j=1 ,2; and of   VE
c
(τ,v), with τ =3y e a r s .F o rV E c(τ,v)w ef o c u so nt h ee n do f
follow-up t = τ because it is most important scientiﬁcally to understand durability of
vaccine eﬃcacy.
The functions VE(t,v)a n dV E c(t,v) can be complicated functions of v even when
Tk and Vk are independent. Although independence may be unlikely in applications,
to keep the simulation model simple we focus on this case. Limited simulations under
dependence showed comparable performance of the procedures. The cumulative inci-
dence function for group k is taken as Fk(t,v)=P{Tk ≤ t}fVk(v), where fVk is the
density of Vk. In the ﬁrst set of simulations we specify T1 and T2 to be exponential with
parameters θλ2 and λ2, respectively, so that the cumulative vaccine eﬃcacy by time τ
irrespective of the mark V is given by VEc(τ)=1−(1−exp(−λ2θτ))/(1−exp(−λ2τ)),
where λ2 is the constant infection hazard rate in the placebo group. Here θ is the con-
stant infection hazard ratio between groups 1 and 2. In the second set of simulations
we specify non-proportional hazards, to examine the eﬀect of violating the assumption
used by the semiparametric tests. In this case Vk and T2 are distributed the same as
above, and T1 is set as T1 =
√
X1,w h e r eX1 is exponential with parameter λ1, implying
λ1(t)=2 λ1t.
We consider two true values of VEc(τ), 0.67 and 0.33. To evaluate the size of the
tests of H0
0 we also consider VEc(τ)=0 .0. We select λ2 so that 50% of placebo recipients
are expected to be infected by τ = 36 months. In addition we generate 10% random
drop-out before 36 months.
Next, we specify
fVk(v)=
 
βk
 
1.51/βk − 0.51/βk
  −1
(v +0 .5)
(1/βk)−1 for 0 ≤ v ≤ 1.
Here βk = 1 corresponds to λk(t,v) not depending on v,w i t hE(Vk)=1 /2, and βk =
0.5, 0.25 correspond to increasing levels of dependence between λk(t,v)a n dv,w i t h
15E(Vk) = 2/3 and 4/5, respectively. The cumulative vaccine eﬃcacy is given by
VEc(τ,v)=1− (1 − VEc(τ))
β2
β1
 
1.51/β2 − 0.51/β2
1.51/β1 − 0.51/β1
 
(v +0 .5)
(1/β1)−(1/β2) .
Note that VE(τ,v)=V E ( τ)a n dV E c(τ,v)=V E c(τ) if and only if β1 = β2, so that
setting β2/β1 =1 .0r e p r e s e n t sH0.F u r t h e r m o r e β2/β1 > 1 implies VE(τ,v)a n d
VEc(τ,v) decrease with v, so the extent of departure from H0 increases with β2/β1.
We set the true (β1,β 2) to be (1.0, 1.0), (0.50, 1.0), (0.25, 1.0), (0.50, 0.50), or (0.25,
0.25). We also consider a two-sided alternative with fV 2(v) a uniform density and
fV 1(v)=16
3 vI(v<1
2)+( 8
3 − 8
3v)I(v ≥ 1
2). Results for this case are given under the
heading “2-sided” in Tables 1 and 2.
The weight process Hn(·) of (3.8) is used for the test statistics. For kernel estimation
of λk(t),k=1 ,2, the Epanechnikov kernel K(x)=0 .75(1 − x2)I(|x|≤1) is used. For
each simulation iteration the optimal bandwidth bk is chosen to minimize an asymptotic
approximation to the mean integrated squared error of ˆ λk (Andersen et al., 1993, p.
240) separately for k =1 ,2, and the method of Gasser and M¨ uller (1979) is used to
correct for bias in the tails. An alternative approach would jointly optimize (b1,b 2)f o r
estimating the hazard ratio. Based on Kelsall and Diggle (1995), joint optimization does
not provide appreciable eﬃciency gains unless the hazards in the two groups are fairly
similar. For the HIV vaccine application, it is most interesting to assess the relationship
of vaccine eﬃcacy on viral divergence when there is some eﬃcacy (i.e., the hazards are
unequal). For this reason we optimized bk for the hazard functions separately.
The nominal level of the tests is set at 0.05, and critical values are calculated using
500 replicates of the Gaussian multipliers technique described in Section 3.2. For esti-
mation, the mark-bandwidths bvk were chosen to achieve reasonably smooth estimates,
which was accomplished with bv1 = bv2 =0 .20. Bias, coverage probability of the 95%
conﬁdence intervals (4.2), and variance estimation of   VE
c
(τ,v) are evaluated at the
three mark-values v =0 .30,0.50,0.80. We choose n = 100,200 or 400 and in addition
to the 50% administrative censoring for the failure times at 36 months we use a 10%
random censoring rate in each arm. The performance statistics are calculated based on
1000 simulated datasets.
16The results in Table 1 indicate that the tests of H0
0 have appropriate sizes and high
powers. When VE(t,v) declines with v, they have greater power than the Cox model
Wald test of VE(t) = 0. Therefore accounting for the mark variable can substantially
improve eﬃciency. This is especially the case for ˆ U1
2, although this test has less power
than the Cox model test if VE(t,v) is constant in v (i.e., β1 = β2). In contrast, the
power of ˆ U1
1 is less sensitive to how strongly VE(t,v)v a r i e si nv. The corresponding
2-sided tests ˆ U1
3 and ˆ U1
4 show a similar comparative pattern but with lower power for
the one-sided alternatives.
The results in Table 2 show that the tests of H0 perform well at moderate sample
sizes. Somewhat surprisingly, for small/moderate samples the semiparametric tests did
not provide greater power than the nonparametric tests in the case that the failure
times had proportional hazards. To explain this, note that the nonparametric and
semiparametric test processes involve contrasts ˆ Λ1(dt,v) − ˆ r(t)ˆ Λ2(dt,v), with ˆ r(t)=
ˆ λ1(t)/ˆ λ2(t) and exp(ˆ β), respectively, and the alternative hypothesis involves changes of
λ1(t,v)/λ2(t,v)i nv— but not in t.S i n c eˆ Λk(dt,v)a n dˆ λk(t) approximately “track”
each other in t, the nonparametric test process can reduce the noise from perturbations
of ˆ λ1(t)/ˆ λ2(t)i nt, whereas the semiparametric test process cannot dampen this noise.
The small simulation study under non-proportional hazards, with H0 true with
(β1,β 2) = (1.0,1.0), (0.5,0.5), or (0.25,0.25), demonstrates (as predicted from the theory)
that the semiparametric tests are not valid when the marginal proportional hazards
condition is not met. The empirical sizes of the tests frequently missed 0.05 by an
amount more than 2 or 3 Monte Carlo standard deviations (results not shown).
The results in Table 3 show that for moderate samples,   VE
c
(36,v)i su n b i a s e da t
some parameter conﬁgurations and biased at others, and that the bias becomes negligible
as the number of infections grows large. The conﬁdence intervals for VEc(36,v)h a v e
correct coverage probability in large samples and usually perform well at smaller sample
sizes, but have too-small coverage probability for the same values of VEc(36,v)a tw h i c h
the estimator is substantially negatively biased. The asymptotic variance estimates of
  VE
c
(36,v) tracked the Monte Carlo variance estimates fairly closely, verifying acceptable
accuracy of the variance estimators (not shown).
17The simulation study was programmed in Fortran, with pseudorandom-numbers
generated with internal Fortran functions. This program and a data analysis program
are available upon request.
6. Application
We apply the methods to the data from the VaxGen trial described in the Introduc-
tion. Figure 1 shows boxplots of the three percent amino acid mismatch distances of the
infecting HIV viruses to the nearest virus (MN or GNE8) represented in the tested vac-
cine. The testing procedures were implemented using the same weight function Hn(·),
kernel K(·), and procedures for optimal bandwidth selection and tail correction that
were used in the simulation experiment. P-values were approximated using 10,000 sim-
ulations. The MISE-optimized bandwidths bk for the estimated hazards of infection
ˆ λ1(·)a n dˆ λ2(·)w e r eb1 =1 . 8 3m o n t h sa n db2 = 2.10 months. For the neutralizing face
core distances, the four tests of H0
0 :V E ( t,v) = 0 gave p-values spanning 0.05 to 0.32
(Figure 1(d)), with ˆ U1
2 rejecting H0
0 at level 0.05. Based on this evidence (albeit weak)
that VE(t,v)  =0 ,w eg oo nt ot e s tH0 :V E ( t,v)=V E ( t). Neither nonparametric test
rejected H0 (Figure 1(d)). The proportional hazards assumption seemed reasonable
based on a goodness-of-ﬁt test (p =0 .35), justifying the semiparametric tests of H0,
which gave nonsigniﬁcant results (Figure 1(d)). To illustrate the graphical procedure,
Figure 2 shows the test process Lnp
n (t,v) together with 8 randomly selected realization
of the null test process Lnp∗
n (t,v), using a unit weight process Hn(·)=1 . The maximum
absolute deviation of Lnp
n (t,v)i nt is larger than that for all but one of the null test
processes. Figure 1 panels (e)-(f) show p-values of the tests for the other two distances,
which all exceeded 0.05.
With bandwidths bv1 and bv2 separately optimized using 2-fold cross-validation, we
next estimated VEc(36,v)a n dV E dc(36,v) (Figure 3). The VEc(36,v)c u r v e sa r ee s t i -
mated with reasonable precision at mark values v not in the tail regions, and VEdc(36,v)
is estimated with reasonable precision for v not in the left tail, with precision increasing
with v. For neutralizing face core distances the estimates of VEc(36,v)a n dV E dc(36,v)
in the regions of precision diminished with viral distance, which suggests that the close-
18ness of match of amino acids in the exposing strain versus vaccine strain in the core
amino acids may have impacted the ability of the vaccine to stimulate protective an-
tibodies that neutralized the exposing strain. The borderline signiﬁcant result is in-
triguing, because this distance has the soundest biological rationale– three-dimensional
structural analysis has demonstrated that the amino acid positions used for this distance
constitute conserved neutralizing antibody epitopes (Wyatt et al., 1998).
7. Concluding Remarks
Nonparametric and semiparametric methods have been developed for testing and
estimation of relative risks taking into account a continuous mark variable observed only
at uncensored failure times, and for evaluating the relationship between the relative risk
and the mark. We showed that if the mark-speciﬁc relative risk varies with the mark,
then a standard Cox model test of a unit hazard ratio (ignoring the mark) is less powerful
(and sometimes much less) than the newly developed nonparametric procedures that
test the null H0
0 : λ1(t,v)/λ2(t,v) = 1 of a unit mark-speciﬁc hazard ratio. This
ﬁnding raises the novel idea to consider accounting for the mark variable in secondary
hypothesis tests in clinical trials for which there are strong reasons to suspect that the
mark-speciﬁc relative risk is monotone in the mark. Among the statistics developed
for testing H0
0, ˆ U1
1 or ˆ U1
2 are recommended, with the choice between them depending
on how strongly the mark-speciﬁc relative risk varies with the mark in the alternative
hypothesis of interest.
For testing dependency of the mark-speciﬁc relative risk on the mark, H0 : λ1(t,v)/
λ2(t,v)=λ1(t)/λ2(t), the simulations suggest that the nonparametric procedures per-
form better than their semiparametric counterparts that assume proportional marginal
hazards. The test based on ˆ U
np
1 is recommended.
Although the methods were motivated by a particular scientiﬁc problem (the ques-
tion in HIV vaccine eﬃcacy trials of if and how eﬃcacy of the tested vaccine varies
with the genetic distance of the infecting HIV strain), we emphasize that they pro-
vide a general solution to the two-sample survival analysis problem with a continuous
mark variable, which may have many applications. An appeal of the procedures devel-
19oped here is that they are based on a mark-speciﬁc version of the widely-applied and
well-understood Nelson–Aalen-type nonparametric maximum likelihood estimator, and
naturally extend the scope of methods that have been developed for competing risks
data with discrete (cause-of-failure) marks.
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Appendix: Proofs of Theorems
Proofs of the results in Section 3.2 are presented for the nonparametric tests of H0,
involving Lnp
n (t,v)a n dˆ U
np
j with r(t)=λ1(t)/λ2(t)a n dˆ r(t)=ˆ λ1(t)/ˆ λ2(t). The proofs
are similar and simpler for the other tests and are omitted.
The following results summarized in Lemma 1 and Lemma 2 are to be used in the
proof of Proposition 1. Lemma 1 applies to either of the kernel estimators ˆ λk(t) deﬁned
in (2.2), k =1 ,2. For simplicity, we state the lemma for a single estimator of this form,
with the subscript k suppressed throughout.
Lemma 1 Assume that λ(t) is continuously diﬀerentiable and bounded away from zero
on t ∈ [0,τ + δ], P(C ≥ τ + δ) > 0 and that the symmetric kernel function K(t) has
support on [−1,1] and is twice continuously diﬀerentiable. Let a>0 and b → 0.
(a) Suppose nb3/logb−1 →∞ . Then the total variation of ˆ λ(t) is bounded in probability
on [a,τ].
(b) Suppose nb/logb−1 →∞ .T h e nsupa≤t≤τ |ˆ λ(t) − λ(t)|
P −→0.
20Proof of Lemma 1.
Let λ∗(t)=
  τ+δ
0 b−1K((t − s)/b)λ(s)P(Y (s)  =0 )ds. Then there exists an n0 such
that λ∗(t)=
  1
−1 K(x)λ(t − bx)P(Y (t − bx)  =0 )dx,f o rt ∈ [a,τ], n ≥ n0.S i n c e Y (·)
is a non-increasing risk process and λ(t) has total variation bounded in probability, it
is easy to see that λ∗(t) has bounded variation on [a,τ] uniformly in n.N o t e t h a t
λ∗(t)=Eˆ λ(t) and decompose
ˆ λ(t) − λ(t)=ˆ λ(t) − λ∗(t)+λ∗(t) − λ(t).
To prove part (a), it is suﬃcient to show that ˆ λ(t) − λ∗(t) has total variation bounded
in probability. By the mean value theorem, it suﬃces to show that the derivative
vn(t)=
d
dt
(ˆ λ(t) − λ∗(t)) =
  τ+δ
0
b−2K ((t − s)/b)(dˆ Λ(s) − λ(s)P(Y (s)  =0 ) ds)
is uniformly bounded in probability over [a,τ], where K (x) is the derivative of K(x).
Let V (t)=
  1
−1(K (s))2 dsλ(t)/y(t), where y(t)=EY(t)/n.L e tWn(t)=( nb/V (t))1/2
bvn(t)a n dMn =s u p 0≤t≤τ |Wn(t)|. We also deﬁne rn =( 2 l o g ( τn/b))1/2 and dn =
rn +( l o gw∗)/rn,w h e r ew∗ =( 2 π)−1[
  1
−1(K  (x))2 dx/
  1
−1(K (x))2 dx]1/2 and τn is the
highest order statistic in [0,τ]. Thus τn
P −→τ. Following the proofs of Proposition 3.1,
Proposition 3.2 and Theorem 4.B of Yandell (1983), it can be shown that for all x,
P{rn(Mn − dn) <x }→exp(−2e−x),
as nb →∞ . The only thing that we need to note here is that we can treat K (t)a st h e
weight function w of Yandell (1983). The conditions K (t) ≥ 0a n d
  1
−1 K (s)ds =1
are not needed in Yandell’s proofs of Proposition 3.1, Proposition 3.2 and Theorem 4.B.
Therefore Mn = Op(dn)=Op((log b−1)1/2)a n dvn(t)=Op((logb−1/nb3)1/2) uniformly
in t ∈ [0,τ]. This proves part (a).
Part (b) follows directly from Proposition 3.1, Proposition 3.2 and Theorem 4.B of
Yandell (1983).
Lemma 2 Let I =[ a,b]×I0 ⊂ RK where I0 is a K−1-dimensional rectangle. Let D(I)
be the Skorohod space of the functions on I that are continuous from above with limits
21from below. Assume that the random processes gn(·,·) and g(·,·) have sample paths
in D(I), sup(t,x)∈I |gn(t,x) − g(t,x)|
P −→0,a n dgn(·,x) and g(·,x) have total variations
bounded in probability, uniformly in x. Assume that the processes Qn(t,x)
D −→Q(t,x) in
D(I).T h e n
sup
(t,x)∈I
|
  t
a
Qn(s,x)gn(ds,x) −
  t
a
Qn(s,x)g(ds,x)|
P −→0( A . 1 )
sup
(t,x)∈I
|
  t
a
gn(s−,x)Qn(ds,x) −
  t
a
g(s−,x)Qn(ds,x)|
P −→0, (A.2)
where g(s−,·) = limu→s,u<sg(u,·) and gn(s−,·) is deﬁned similarly.
Proof of Lemma 2.
Since Qn(t,x)
D −→Q(t,x)i nD(I), Qn(t,x) is tight by Bickel and Wichura (Theorem
2, 1971). It follows that for any  >0, η>0, there exists a partition a = t1 <t 1 <
...<t m+1 = b and n0 such that
P(m a x
1≤j≤m
sup
x∈I0
sup
t∈[tj,tj+1)
|Qn(t,x) − Qn(tj,x)| >  ) <η , for n ≥ n0. (A.3)
Also, since Qn(t,x) converges weakly and gn(·,x)a n dg(·,x) have bounded variations
in probability uniformly in x, for any η>0, there exists B>0a n dn1 ≥ n0 such that,
for n ≥ n1,
P(s u p
(t,x)∈I
|Qn(t,x)| >B ) <η (A.4)
P
 
sup
x∈I0
   b
a
|gn(ds,x)| +
  b
a
|g(ds,x)|
 
>B
 
<η . (A.5)
For each m, deﬁne Qm
n (t,x)=Qn(tj,x)f o r( t,x) ∈ [tj,t j+1)×I0, j =1 ,...,m.L e tCn =
sup(t,x)∈I |Qn(t,x) − Qm
n (t,x)|.T h e n Cn =m a x 1≤j≤m supx∈I0 supt∈[tj,tj+1) |Qn(t,x) −
Qn(tj,x)|.N o t et h a t
sup
(t,x)∈I
 
 
   
  t
a
Qn(s,x)gn(ds,x) −
  t
a
Qn(s,x)g(ds,x)
 
 
   
≤ sup
(t,x)∈I
 
 
   
  t
a
(Qn(s,x) − Qm
n (s,x))gn(ds,x)
 
 
    +s u p
(t,x)∈I
 
 
   
  t
a
(Qn(s,x) − Qm
n (s,x))g(ds,x)
 
 
   
+s u p
(t,x)∈I
 
 
   
  t
a
Qm
n (s,x)(gn(ds,x) − g(ds,x))
 
 
   
≤ Cn
 
sup
x∈I0
  b
a
|gn(ds,x)| +s u p
x∈I0
  b
a
|g(ds,x)|
 
+2 m sup
(t,x)∈I
|Qn(t,x)| sup
(t,x)∈I
|gn(t,x) − g(t,x)|.
22Thus, for any δ>0a n dη>0, choose B as in (A.4) and (A.5). Take   in (A.3) to be
δ/(2B)a n dn0 corresponding to the  .W eh a v e ,f o rn ≥ n1,
P
 
sup
(t,x)∈I
 
 
 
 
  t
a
Qn(s,x)gn(ds,x) −
  t
a
Qn(s,x)g(ds,x)
 
 
 
  >δ
 
≤ P
 
Cn
 
sup
x∈I0
  b
a
|gn(ds,x)| +s u p
x∈I0
  b
a
|g(ds,x)|
 
>δ / 2
 
+P
 
2m sup
(t,x)∈I
|Qn(t,x)| sup
(t,x)∈I
|gn(t,x) − g(t,x)| >δ / 2
 
≤ P
 
sup
x∈I0
  b
a
|gn(ds,x)| +s u p
x∈I0
  b
a
|g(ds,x)| >B
 
+ P{Cn >δ / (2B)}
+P
 
sup
(t,x)∈I
|Qn(t,x)| >B } + P{ sup
(t,x)∈I
|gn(t,x) − g(t,x)| >δ / (4mB)
 
≤ 3η + P
 
sup
(t,x)∈I
|gn(t,x) − g(t,x)| >δ / (4mB)
 
.
Since sup(t,x)∈I |gn(t,x) − g(t,x)|
P −→0, we have
limsup
n→∞
P
 
sup
(t,x)∈I
 
   
 
  t
a
Qn(s,x)gn(ds,x) −
  t
a
Qn(s,x)g(ds,x)
 
   
  >δ
 
≤ 3η.
Since η is arbitrary, this proves (A.1). The proof of (A.2) follows by integration by
parts.
Proposition 1 Given the conditions of Theorem 1,
Lnp
n (t,v) −
 
n1n2
n
  t
a
Hn(s)[Λ1(ds,v) − r(s)Λ2(ds,v)]
D −→Lnp(t,v)( A . 6 )
in D([a,τ] × [0,1]).
Proof of Proposition 1.
Using the central limit theorem for empirical processes (cf. Gilbert et al., 2004,
(A.4)),
√
nk(Nk(t,v)/nk − γk(t,v),Y k(t)/nk − yk(t))
D −→(G
(k)
1 (t,v),G
(k)
2 (t)) (A.7)
in D([0,τ] × [0,1]) × D[0,τ], where G
(k)
1 (t,v)a n dG
(k)
2 (t) are continuous mean zero
Gaussian processes with covariances
Cov(G
(k)
1 (s,u),G
(k)
1 (t,v)) = γk(s ∧ t,u ∧ v) − γk(s,u)γk(t,v),
Cov(G
(k)
2 (s),G
(k)
2 (t)) = yk(s ∨ t) − yk(s)yk(t),
Cov(G
(k)
1 (s,u),G
(k)
2 (t)) = (γk(s,u) − γk(t−,u))I(t ≤ s) − γk(s,u)yk(t).
23Let ˆ Zk(t,v)=
√
nk(ˆ Λk(t,v) − Λk(t,v)). By the functional delta method as used in
(A.7)–(A.8) of Gilbert and Kosorok (2001), we have
ˆ Zk(t,v)
D −→Zk(t,v)( A . 8 )
in D([0,τ] × [0,1]), where the two processes Z1(t,v)a n dZ2(t,v) are independent.
The test process can be decomposed as follows:
Lnp
n (t,v)=
 
n1n2
n
  t
a
Hn(s)[ˆ Λ1(ds,v) − Λ1(ds,v)]
−
 
n1n2
n
  t
a
Hn(s)ˆ r(s)[ˆ Λ2(ds,v) − Λ2(ds,v)] +
 
n1n2
n
  t
a
Hn(s)[Λ1(ds,v) − ˆ r(s)Λ2(ds,v)]
=
 
n2
n
  t
a
Hn(s) ˆ Z1(ds,v) −
 
n1
n
  t
a
Hn(s)ˆ r(s) ˆ Z2(ds,v)
+
 
n1n2
n
  t
a
Hn(s)[r(s) − ˆ r(s)]Λ2(ds,v)+
 
n1n2
n
  t
a
Hn(s)[Λ1(ds,v) − r(s)Λ2(ds,v)].
Under H0, the last term equals zero. By Lemma 1, supa≤s≤τ |ˆ r(s)−r(s)|
P −→0a n dˆ r(s)
has bounded variation in probability on [a,τ]. By Lemma 2, the continuity of ˆ λk(t)a n d
the conditions on Hn(t), we have
Lnp
n (t,v)=
 
n2
n
  t
a
H(s) ˆ Z1(ds,v) −
 
n1
n
  t
a
H(s)r(s) ˆ Z2(ds,v)( A . 9 )
+
 
n1n2
n
  t
a
Hn(s)[r(s) − ˆ r(s)]Λ2(ds,v)+
 
n1n2
n
  t
a
H(s)[Λ1(ds,v) − r(s)Λ2(ds,v)] + op(1).
Let ˆ a(s)=1 /ˆ λ2(s)a n dˆ b(s)=λ1(s)/(λ2(s)ˆ λ2(s)). Let a(s)=1 /λ2(s)a n db(s)=λ1(s)/
(λ2(s))2. The third term of (A.9) equals
 
n1n2
n
  t
a
Hn(s)[−ˆ a(s)(ˆ λ1(s) − λ1(s)) +ˆ b(s)(ˆ λ2(s) − λ2(s))]Λ2(ds,v). (A.10)
Note that
ˆ λk(t)=
1
bk
  τ+δ
0
K
 
t − s
bk
 
dˆ Λk(s)
and
1
bk
  τ+δ
0
K
 
t − s
bk
 
dΛk(s)=λk(t)+O(b2
k),
uniformly in t ∈ [a,τ]. We have, by changing the order of integration and noting the
compact support of the kernel function K(·)o n[ −1,1],
 
n1n2
n
  t
a
Hn(s)ˆ a(s)(ˆ λ1(s) − λ1(s))Λ2(ds,v) (A.11)
24=
 
n1n2
n
  τ+δ
0
   t
a
1
b1
K
 
s − u
b1
 
Hn(s)ˆ a(s)Λ2(ds,v)
 
d(ˆ Λ1(u) − Λ1(u)) + O(
√
nb2
1)
=
 
n1n2
n
  t−b1
a−b1
   t
a
1
b1
K
 
s − u
b1
 
Hn(s)ˆ a(s)Λ2(ds,v)
 
d(ˆ Λ1(u) − Λ1(u))
+
 
n1n2
n
  t+b1
t−b1
   t
a
1
b1
K
 
s − u
b1
 
Hn(s)ˆ a(s)Λ2(ds,v)
 
d(ˆ Λ1(u) − Λ1(u)) + O(
√
nb2
1).
By the uniform convergence of Hn(s)t oH(s)a n dˆ a(s)t oa(s), and the uniform conti-
nuity of H(s)a n da(s), we have
1
b1
  t
a
K
 
s − u
b1
 
Hn(s)ˆ a(s)Λ2(ds,v)=H(u)a(u)Λ 
2u(u,v)+op(1),
uniformly in u ∈ (a−b1,t+b1), 0 ≤ t ≤ τ,w h e r eΛ  
2u(u,v)=∂Λ2(u,v)/∂u. By Lemma 1,
ˆ a(s) has bounded variation in probability over [a,τ]. Since Hn(s) has uniform bounded
variation as well, we have that the process
  t
a b−1
1 K((s − u)/b1)Hn(s)ˆ a(s)Λ 
2s(s,v)ds
is of bounded variation in u in probability uniformly in v ∈ [0,1] and t ∈ [0,τ], and
H(u)a(u)Λ 
2u(u,v) is of bounded variation uniformly in v ∈ [0,1]. Since
√
n1(ˆ Λ1(u) −
Λ1(u)) converges weakly, it follows from Lemma 2 that (A.11) equals
 
n1n2
n
  t−b1
a−b1
H(u)a(u)Λ 
2u(u,v)d(ˆ Λ1(u) − Λ1(u)) + O(
√
nb2
1)+O(b1)
=
 
n2
n
  t
a
H(s)a(s)Λ 
2s(s,v) ˆ Z1(ds,1) + O(
√
nb2
1)+op(1). (A.12)
Similarly,
 
n1n2
n
  t
a
Hn(s)ˆ b(s)(ˆ λ2(s) − λ2(s))Λ2(ds,v)
=
 
n1
n
  t
a
H(s)b(s)Λ 
2s(s,v)d ˆ Z2(ds,1) + O(
√
nb2
2)+op(1). (A.13)
By (A.9)–(A.13), under
√
nb2
k → 0, as n →∞for k =1 ,2, we have
Lnp
n (t,v)=
 
n2
n
   t
a
H(s) ˆ Z1(ds,v) −
  t
a
H(s)a(s)Λ 
2s(s,v) ˆ Z1(ds,1)
 
−
 
n1
n
   t
a
H(s)r(s) ˆ Z2(ds,v) −
  t
a
H(s)b(s)Λ 
2s(s,v)d ˆ Z2(ds,1)
 
+
 
n1n2
n
  t
a
Hn(s)[Λ1(ds,v) − r(s)Λ2(ds,v)] + op(1).
Note that b(s)=r(s)a(s). It follows by the continuous mapping theorem that
Lnp
n (t,v) −
 
n1n2
n
  t
a
Hn(s)[Λ1(ds,v) − r(s)Λ2(ds,v)]
D −→Lnp(t,v).
25in D([a,τ] × [0,1]).
Proof of Theorem 2.
Under H1,t h er a t i oλ1(t,v)/λ2(t,v)i n c r e a s e sw i t hv for all t ∈ [0,τ]. Since λk(t)=
  1
0 λk(t,v)dv, k =1 ,2, and under H1,
λ1(t,0)
λ2(t,0)
≤
λ1(t,v)
λ2(t,v)
≤
λ1(t,1)
λ2(t,1)
,
we have
λ1(t,0)
λ2(t,0)
≤
λ1(t)
λ2(t)
≤
λ1(t,1)
λ2(t,1)
.
Under the assumptions of Theorem 2,
λ1(t,v)
λ2(t,v) is continuous in v ∈ [0,1] for every t ∈ [0,τ].
By the intermediate-value theorem, for every t ∈ [0,τ]t h e r ee x i s t savt ∈ [0,1] such that
r(t)=
λ1(t)
λ2(t)
=
λ1(t,vt)
λ2(t,vt)
.
We choose vt to be the smallest v satisfying this equality. It follows that vt is a continuous
function of t and
λ1(t,v)
λ2(t,v)
≤ r(t)f o r v ≤ vt and
λ1(t,v)
λ2(t,v)
≥ r(t)f o r v ≥ vt.
Note that the inequality under H1 is strict for some (t,v), λk(t)=
  1
0 λk(t,v)dv and
the functions λ1(t,v)a n dλ2(t,v) are continuous. There exists an open neighborhood
of t such that 0 <v t < 1. Let a>0a n ds1 <s 2 be such that vt − a,vt + a ∈ (0,1) for
t ∈ [s1,s 2]. Then
  vt+a
vt
H(t)(λ1(t,v) − r(t)λ2(t,v))dv −
  vt
vt−a
H(t)(λ1(t,v) − r(t)λ2(t,v))dv > 0,
for t ∈ [s1,s 2]. Since the integrals above are uniform continuous functions of (t,vt)a n d
vt is uniform continuous, there exists a neighborhood [t1,t 2] ⊂ [s1,s 2]a n d[ v1,v 2] ⊂ [0,1]
such that
  t2
t1
  v2
v1+v2
2
H(s)(λ1(s,v)−r(s)λ2(s,v))dv ds−
  t2
t1
  v1+v2
2
v1
H(s)(λ1(s,v)−r(s)λ2(s,v))dv ds ≥ c,
where c is a positive constant. Let δn(t1,t 2,v 1,v 2) be the left side of the above expression
with H(s) replaced by Hn(s). Since Hn(t)
P −→H(t) > 0 uniformly in t ∈ [0,τ], we have
26 
n1n2
n δn(t1,t 2,v 1,v 2)
P −→∞, as n →∞ . By Proposition 1,
Δr
n(t2,v 1,v 2) − Δr
n(t1,v 1,v 2) −
 
n1n2
n
δn(t1,t 2,v 1,v 2)
=
 
(Lr
n(t2,v 2) − Lr
n(t1,v 2)) − (Lr
n(t2,
v1 + v2
2
) − Lr
n(t1,
v1 + v2
2
))
 
−
 
(Lr
n(t2,
v1 + v2
2
) − Lr
n(t1,
v1 + v2
2
)) − (Lr
n(t2,v 1) − Lr
n(t1,v 1))
 
−
 
n1n2
n
δn(t1,t 2,v 1,v 2)
D −→
 
(Lr(t2,v 2) − Lr(t1,v 2)) − (Lr(t2,
v1 + v2
2
) − Lr(t1,
v1 + v2
2
))
 
−
 
(Lr(t2,
v1 + v2
2
) − Lr(t1,
v1 + v2
2
)) − (Lr(t2,v 1) − Lr(t1,v 1))
 
(A.14)
Applying Slutsky’s Theorem, we have ˆ Ur
1
P −→∞ as n →∞ .
We note that, under H2,t h e r ee x i s t[ t1,t 2]a n d[ v1,v 2] such that
   
 
 
 
  t2
t1
  v2
v1+v2
2
H(s)(λ1(s,v) − r(s)λ2(s,v))dv ds −
  t2
t1
  v1+v2
2
v1
H(s)(λ1(s,v) − r(s)λ2(s,v))dv ds
   
 
 
  ≥ c,
where c is a positive constant. Otherwise, H(s)(λ1(s,v) − r(s)λ2(s,v)) is a constant
function of (s,v), which would be zero since λk(t)=
  1
0 λk(t,v)dv, k =1 ,2. Since
Hn(t)
P −→H(t) > 0 uniformly in t ∈ [0,τ], it follows that
 
n1n2
n |δn(t1,t 2,v 1,v 2)|
P −→∞,
as n →∞ . By (A.14) and Slutsky’s Theorem, we have ˆ Ur
2
P −→∞ as n →∞ .T h i s
completes the proof.
Proof of the tightness for Lnp∗
n (t,v) (remaining piece of Theorem 3 proof).
To show tightness of Lnp∗
n (t,v) given the observed data sequence, it suﬃces to check
a slight extension of the moment conditions of Bickel and Wichura (1971) for stochastic
processes on the plane, cf. McKeague and Zhang’s (1994, page 506) extension of the
moment conditions of Billingsley (1968).
It is suﬃcient to show that n1
−1/2  n1
i=1 ˆ h1i(t,v)W1i in (3.6) is tight given the
observed data sequence. The tightness of the second term follows similarly. Let
B =[ t1,t 2] × [v1,v 2]a n dG =[ s1,s 2] × [x1,x 2] be any pair of neighboring blocks in
[0,τ] × [0,1]. Let ˆ h1i(B)=ˆ h1i(t2,v 2) − ˆ h1i(t2,v 1) − ˆ h1i(t1,v 2)+ˆ h1i(t1,v 1)a n d
Δ(B)=n
−1/2
1
n1  
i=1
ˆ h1i(B)W1i.
27We show that there exists a ﬁnite measure μ0 on [0,τ] × [0,1] such that
E
 
Δ2(B)
 
 
 
 {observed data}
 
≤ μ0(B)+op(1) (A.15)
E
 
Δ2(B)Δ2(G)
 
 
   {observed data}
 
≤ μ0(B)μ0(G)+op(1), (A.16)
where the op(1) term converges to zero in probability independently of (or uniformly
in) B and G. Since a simple linear combination of tight processes is tight, it suﬃces to
check the conditions (A.15) and (A.16) for each of the four terms in ˆ h1i. However, for
ease of notation we use ˆ h1i to represent any one of the four terms.
By the uniform convergence of Hn(s), Yk(s), Nk(s,v)/nk,ˆ a(s), and ˆ Λ 
2s(s,v)o n
[a,τ] × [0,1], a simple probability argument yields that
E
 
Δ2(B)
 
 
   {observed data}
 
≤ n−1
1
n1  
i=1
(ˆ h1i(B))2 + op(1) (A.17)
E
 
Δ2(B)Δ2(G)
 
 
 
 {observed data}
 
≤ 6n−2
1
n1  
i=1
(ˆ h1i(B))2
n1  
i=1
(ˆ h1i(G))2 + op(1). (A.18)
Then (A.15) and (A.16) follow from working with each of the four terms of ˆ h1i in (A.17)
and (A.18). The details are omitted.
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30Table and Figure Legends
Table 1. Empirical Power (× 100%) for Testing H0
1 and H0
2
Table 2. Empirical Power (× 100%) for Testing H1 and H2
Table 3. Bias of   VE
c
(36,v) and 95% Coverage Probability of VEc(36,v)
Figure 1. The top panel shows boxplots of amino acid distances in HIV gp120 between
the infecting viruses and the nearest vaccine strain MN or GNE8, for the three studied
HIV distances. The bottom panel shows p-values of the studied tests: Cox corresponds
to the Wald test in the Cox model; 11, 12, 13, 14 correspond to ˆ U1
1, ˆ U1
2, ˆ U1
3, ˆ U1
4;n 1 ,n 2 ,
correspond to ˆ U
np
1 , ˆ U
np
2 ; s1, s2, correspond to ˆ U
sp
1 , ˆ U
sp
2 .
Figure 2. For the neutralizing face core distances, the top-left panel shows the observed
test process Lnp
n (t,v) and the other panels show 8 randomly selected realizations of the
simulated null test process Lnp∗
n (t,v).
Figure 3. The left panels show point and 95% conﬁdence interval estimates of VEc(36,v)=
1 − F1(36,v)/F2(36,v) versus the HIV gp120 amino acid distance between infecting
viruses and the nearest vaccine antigen MN or GNE8, for the three studied HIV dis-
tances. The right panels show correspondingpoint and interval estimates of VEdc(36,v)=
1 − P(T1 ≤ 36,V 1 ≤ v)/P(T2 ≤ 36,V 2 ≤ v). The dashed horizontal line is the overall
vaccine eﬃcacy estimate   VE
c
(36) = 0.048.
31Table 1. Empirical Power (× 100%) for Testing H0
1 and H0
2
VE(τ)=0 V E ( τ)=0 .33 VE(τ)=0 .67
β1 β1 β1
nk Test Altern. 11 0 . 5 0 . 2 5 2-sided 1 0.5 0.25 2-sided
100 Cox1 5.2 65.1 65.1 65.1 61.8 99.9 99.9 99.9 99.8
(48)2 ˆ U1
1 H0
1 7.9 68.1 72.3 78.8 58.7 99.8 100 100 96.8
ˆ U1
2 H0
1 7.7 58.5 81.0 97.8 56.5 97.8 100 100 97.7
ˆ U1
3 H0
2 5.9 55.4 60.2 69.7 47.3 98.9 99.5 100 94.8
ˆ U1
4 H0
2 6.7 47.6 71.8 94.8 43.1 96.8 99.3 100 94.6
200 Cox 5.0 90.6 90.6 90.6 100 100 100 100 100
(95)2 ˆ U1
1 H0
1 5.0 92.7 94.3 97.2 91.5 100 100 100 100
ˆ U1
2 H0
1 5.3 86.0 98.4 100 88.1 100 100 100 100
ˆ U1
3 H0
2 7.0 87.5 90.3 94.7 84.7 100 100 100 100
ˆ U1
4 H0
2 5.3 81.0 95.4 100 79.4 100 100 100 100
400 Cox 5.8 99.7 99.7 99.7 100 100 100 100 100
(190)2 ˆ U1
1 H0
1 6.6 99.9 99.9 100 99.5 100 100 100 100
ˆ U1
2 H0
1 6.0 99.0 100 100 98.8 100 100 100 100
ˆ U1
3 H0
2 5.3 99.6 99.9 100 99.0 100 100 100 100
ˆ U1
4 H0
2 5.2 97.9 100 100 97.6 100 100 100 100
1Test statistic is a Wald Z-statistic based on the standard Cox model that ignores the
mark.
2Average number of subjects infected in group 2 (placebo).
32Table 2. Empirical Power (× 100%) for Testing H1 and H2
VE(τ)=0 .33 VE(τ)=0 .67
β1 β1
nk Test Altern. 1 0.5 0.25 2-sided 1 0.5 0.25 2-sided
100 ˆ U
np
1 H1 6.4 21.8 59.0 42.7 7.1 17.0 35.2 22.9
(48)1 ˆ U
np
2 H2 6.2 15.9 47.7 43.3 6.7 12.2 26.1 20.4
ˆ U
sp
1 H1 6.2 18.3 52.9 35.8 5.7 12.8 30.2 17.8
ˆ U
sp
2 H2 4.4 11.1 41.4 38.8 3.5 7.3 18.7 15.3
200 ˆ U
np
1 H1 6.3 32.4 87.0 78.3 6.7 21.0 62.7 48.8
(95)1 ˆ U
np
2 H2 6.8 23.0 81.4 80.9 6.5 14.3 54.2 51.4
ˆ U
sp
1 H1 5.6 29.7 84.8 76.8 5.5 20.0 61.1 46.3
ˆ U
sp
2 H2 5.4 20.8 79.5 81.4 4.8 13.2 49.6 45.6
400 ˆ U
np
1 H1 5.8 48.2 99.5 98.3 6.2 33.7 93.3 87.4
(190)1 ˆ U
np
2 H2 5.2 35.8 98.6 98.7 5.8 25.4 89.2 90.4
ˆ U
sp
1 H1 5.4 46.7 99.0 98.3 5.5 32.7 92.9 86.1
ˆ U
sp
2 H2 4.8 35.3 98.5 98.7 5.1 23.8 87.9 89.4
1Average number of subjects infected in group 2 (placebo).
33Table 3. Bias of   VE
c
(36,v) and 95% Coverage Probability of VEc(36,v)
VE(τ)=0 .0V E ( τ)=0 .67 VE(τ)=0 .33
β1 β1 β1
nk v 1 1 0.5 0.25 1 0.5 0.25
Average Bias × 100
100 (48)1 0.3 -6.3 −2.3 −6.3 −31.6 −2.5 −5.0 −20.8
0.5- 5 . 8 −1.3 −2.6 −13.7 −3.6 −3.6 −9.0
0.8- 6 . 3 −3.7 −3.0 −3.6 −5.2 −5.1 −9.6
200 (95)1 0.3- 2 . 8 −0.1 −1.6 −13.0 −0.9 −1.6 −9.0
0.5- 1 . 6 −0.0 −0.9 −4.8 −1.0 −2.2 −6.0
0.8- 3 . 5 −0.5 −0.6 −1.5 −2.1 −2.7 −5.4
400 (190)1 0.3- 1 . 4 −0.0 −0.4 −3.7 −0.2 −0.1 −3.0
0.5- 1 . 1 −0.1 −0.8 −3.6 −0.0 −0.9 −4.6
0.8- 0 . 8 −0.3 0.1 −0.9 −0.3 −0.2 −2.4
Coverage Probability × 100%
100 (48)1 0.3 97.6 97.9 96.0 73.9 97.2 97.3 86.6
0.5 97.7 98.6 97.5 90.0 97.5 97.9 95.2
0.8 94.7 96.0 96.2 95.4 94.6 94.9 96.1
200 (95)1 0.3 96.7 96.5 96.8 77.1 97.8 97.1 88.0
0.5 97.2 96.7 97.5 93.8 96.8 97.5 96.5
0.8 94.9 94.4 95.3 95.8 94.5 95.6 95.9
400 (190)1 0.3 96.8 95.4 96.4 87.8 96.8 97.3 92.2
0.5 96.4 96.3 95.9 93.6 96.5 97.2 96.4
0.8 96.9 96.0 96.3 96.7 96.2 96.8 96.8
1Average number of subjects infected in group 2 (placebo).
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(a) Neutralizing Face Core 
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(b) Neutralizing Face Core 
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(c) Neutralizing Face Core + V2/V3 
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(d) Neutralizing Face Core + V2/V3 
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(e) V3 loop 
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(f) V3 loop